Progesterone plays an essential role in breast development and cancer formation. The local metabolism of progesterone may limit its interactions with the progesterone receptor (PR) and thereby act as a prereceptor regulator. Selective loss of AKR1C1, which encodes a 20␣-hydroxysteroid dehydrogenase [20␣-HSD (EC 1.1.1.149)], and AKR1C2, which encodes a 3␣-hydroxysteroid dehydrogenase [3␣-HSD (EC 1.1.1.52)], was found in 24 paired breast cancer samples as compared with paired normal tissues from the same individuals. In contrast, AKR1C3, which shares 84% sequence identity, and 5␣-reductase type I (SRD5A1) were minimally affected. Breast cancer cell lines T-47D and MCF-7 also expressed reduced AKR1C1, whereas the breast epithelial cell line MCF-10A expressed AKR1C1 at levels comparable with those of normal breast tissues. Immunohistochemical staining confirmed loss of AKR1C1 expression in breast tumors. AKR1C3 and AKR1C1 were localized on the same myoepithelial and luminal epithelial cell layers. Suppression of ARK1C1 and AKR1C2 by selective small interfering RNAs inhibited production of 20␣-dihydroprogesterone and was associated with increased progesterone in MCF-10A cells. Suppression of AKR1C1 alone or with AKR1C2 in T-47D cells led to decreased growth in the presence of progesterone. Overexpression of AKR1C1 and, to a lesser extent, AKR1C2 (but not AKR1C3) decreased progesterone-dependent PR activation of a mouse mammary tumor virus promoter in both prostate (PC-3) and breast (T-47D) cancer cell lines. We speculate that loss of AKR1C1 and AKR1C2 in breast cancer results in decreased progesterone catabolism, which, in combination with increased PR expression, may augment progesterone signaling by its nuclear receptors.
INTRODUCTION
In women, breast cancer is the most common noncutaneous malignancy, and lifetime exposure to ovarian hormones is a well-recognized risk factor for breast cancer development (1, 2) . The actions of both estrogen and progesterone are required for normal growth and maturation of breast tissues, and progesterone is required for terminal duct formation required for lactation (3) . Estrogen can also regulate expression of the progesterone receptor (PR), linking the action of both these two hormones and suggesting a complex interplay between estrogen and regulation of progesterone-dependent genes. Inconsistent results in breast cancer cell lines and animal studies have made it difficult to assess a role of progesterone in either development or promotion of breast cancer (4 -6) . However, women receiving progestin are at greater risk for development of increased mammographic breast density, suggesting greater cellular proliferation (1, 7) , and women in the Women's Health Initiative trial receiving estrogen and a progestin had increased incidence of breast cancer compared with those receiving estrogen alone. These findings strongly suggest that exogenous progestin may be a causative factor for breast tumor development (1, 2, 7, 8) .
The local regulation of hormone synthesis and catabolism are key modifiers for the development and growth of hormone-dependent tumors, including breast cancer (9 -11) . For example, induction of aromatase in breast cancer results in the in situ synthesis of estrogen, promoting tumor growth, and aromatase inhibitors effectively prevent breast cancer recurrence (10, 12) . Thus, estrogen is an effective target for chemoprevention. Similarly, progesterone and/or its metabolites may provide novel targets for chemoprevention of breast cancer or treatment strategies for breast cancer because they act as either growth promoters or cell cycle inhibitors in breast cancer cells (4, 6) . Little is known about the pathways responsible for catabolism of progesterone in the human breast, but in rat placenta, robust induction of 20␣-hydroxysteroid dehydrogenase [20␣-HSD (EC 1.1.1.149)] expression immediately precedes reduction in local progesterone levels at parturition (13, 14) . In humans, a similar increase in placental 20␣-HSD activity occurs, but not in other pathways, implying a common mechanism for the local elimination of progesterone (15, 16) .
The 20␣-HSDs are members of a newly emerging family of NADPHdependent cytosolic oxidoreductases, known as the aldo-keto reductase super gene family (17, 18) . AKR1C1 is one of four highly related human hydroxysteroid dehydrogenases that share Ͼ84% sequence identity but have distinctive substrate specificities and tissue distributions. Three of these AKR1C family members are expressed in the human breast and catalyze the following reactions: (a) AKR1C1 reduces the carbonyl group at the 20 position, and their products are weaker activators of the transcriptional activity of PR (19) ; (b) AKR1C2 encodes for a 3␣-hydroxysteroid dehydrogenase [3␣-HSD (EC 1.1.1.52)] that reduces the carbonyl group at the 3 position of progesterone metabolites that are also weak PR activators (20) ; and (c) AKR1C3, also referred to as 17␤-HSD type V, has minimal 20␣-HSD or 3␣-HSD activity for progesterone (21) . Remarkably, AKR1C2 differs by only 7 of 323 amino acids from AKR1C1 (20, 22) , and all three genes are in close proximity on chromosome 10p14, suggesting evolution by gene duplication (18, 23) .
To assess whether AKR1C may act as a prereceptor regulator of hormone activity by adjusting the availability of hormones to act with their cognate receptors, we recently demonstrated significant reduction of AKR1C2, which catalyzes reduction of dihydrotestosterone to the weak androgen 3␣-androstanediol, in prostate cancer as compared with unaffected tissue (24) . We hypothesized that selective reduction of this key androgen-catabolizing gene would result in maintenance of intracellular levels of dihydrotestosterone in prostate tumors and thereby provide a selective growth advantage for these malignant cells. Because progesterone is likely to modify growth of breast cancer cells (4, 5) , we now report the relative expression of three AKR1C family members in paired breast cancer and normal tissue samples using our recently developed real-time polymerase chain reaction (PCR) methodology (24) . Effects of small interfering RNA (siRNA) suppression of AKR1C1 alone or with AKR1C2 on progesterone metabolism and cellular proliferation were also determined in MCF-10A and T-47D cell lines, indicating that AKR1C1 and body, and color was developed using AEC Substrate Pack (NeoMarkers, Fremont, CA), according to the manufacturer's protocols. Sections were counterstained with Meyer's hematoxylin (NeoMarkers) and mounted in Glycergel (Dako). Both preimmune sera and peptide-preabsorbed antisera were used as controls for IHC staining specificity.
Suppression of AKR1C1 and/or AKR1C2 Expression by Small Interfering RNAs. Four siRNAs were designed by Qiagen, and the resultant sequence was compared with the human genome to assess their cross-reactivity with other AKR1C family members. Ultimately, the following ARK1C1 sequences from M86609 were used and are listed with their percentage similarity to the other AKR1C family members expressed in human breast tissue: Seq-A, AAGCTTTAGAGGCCACCAAAT (85% sequence identity to both AKR1C2 and AKR1C3); Seq-B, AACTGCTGGATTTCTGCAAGT (100% sequence identity to AKR1C2 and 90% sequence identity to AKR1C3); Seq-C, AAAGC-CAGGTGAGGAAGTGAT (100% sequence identity to AKR1C2 and 81% sequence identity to AKR1C3); and Seq-D, AAGGTCACTGAAAAATCT-TCA (100% sequence identity with AKR1C2 and 71% sequence identity with AKR1C3). Transfection of siRNA (Qiagen) was performed according to the manufacturer's protocol, and quantitative real-time PCR was used to monitor suppression of AKR1C family members.
MCF-10A cells (8 ϫ 10 4 ) were seeded onto 6-well plates and grown for 24 hours to approximately 50% confluence. Small interfering RNAs (4.5 g) were diluted in 100 L of suspension buffer, vortexed, and mixed with 15 L of RNAiFect. Cells were incubated with the samples for 5 to 10 minutes at room temperature, the medium was exchanged with 300 L of growth medium, and then cells were allowed to recover for 24 hours. Nonsilencing fluorescein-labeled siRNA (Qiagen) was used as the control for siRNA transfections.
Progesterone Metabolism. MCF-10A cells (8 ϫ 10
4
) were seeded in 6-well tissue culture plates and cultured 24 hours before siRNA transfections. Twentyfour hours after siRNA treatments, 0.2 mCi of [ 3 H]progesterone (Perkin-Elmer Life Science, Boston, MA) was added to the media, and cells were then grown for an additional 16 hours. Medium and cells were harvested separately, and metabolites were separated by thin-layer chromatography. Aliquots (0.5 mL) of lysed cells and supernatants were extracted twice with ethyl acetate:hexane (3:2) and evaporated under nitrogen at 40°C to remove the solvent, and 10 g of progesterone and 20␣-dihydroprogesterone were added as carriers. Extracts were applied to a thin-layer chromatography chromatography plate (Silica gel 60F 254 on 20 ϫ 20-cm aluminum sheet; EM Science, Gibbstown, NJ) and run for 1.5 hours using chloroform:diethyl ether (10:3) as solvent mixture. Locations of progesterone and 20␣-dihydroprogesterone were identified by ultraviolet light, the regions were scraped, and radioactivity was determined by liquid scintigraphy.
T-47D Proliferation Studies. T-47D cells were grown in RPMI 1640 without phenol red with 4% charcoal dextran-treated FBS (HyClone, Logan, UT) and treated with different concentrations of progesterone [0.1% in ethanol (v/v)] or with 0.1% (v/v) ethanol as controls. Cell proliferation assays were performed as described previously (27, 28) with the following modifications: Twenty-four hours before initiation of growth studies, cells were treated with siRNA as described above. A total of 1.5 ϫ 10 4 cells were then seeded into 12-well tissue culture dishes from a common cell culture and grown for an additional 24 hours. Progesterone was then added, and half of the media was replaced on a daily basis. The number of cells in quadruplet wells was then determined daily with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay using Bio-Rad Microplate Reader Model 3550 (Bio-Rad, Hercules, CA) after a standard curve confirmed a linear relationship between cell number and absorbance.
PR-B-Dependent Transactivation Assay. Permanently transfected PC-3 cell lines with varying stable expression levels of AKR1C1, AKR1C2, or AKR1C3 were used for progesterone-dependent transactivation experiments with cotransfection of human PR-B. These PC-3 cell lines were individually transiently transfected with 2 g of pMMTV-Luc (kindly provided by Dr. Franklin, MA) and the Dual Luciferase Activity Kit (Promega). The ratio of firefly to Renilla luciferase activity was normalized to total protein, and luciferase activity of control PC-3 cells was arbitrarily defined as 100 Ϯ SD.
RESULTS
Relative Expression Profile of AKR1C Family Members and SRD5A1 in Paired Breast Tissue Samples. The relative expression profiles of AKR1C1, AKR1C2, AKR1C3, and SRD5A1 were determined in 24 paired breast cancer and normal tissue samples using RNase P as the internal control. RNase P expression was equivalent in tumor and normal tissue (data not shown). Table 1 lists the relative changes in gene expression for AKR1C family members and SRD5A1 in individual pairs of tissue samples, along with clinical features and PR, ER, Her2/neu, and Ki-67 status. A substantial (defined as Ͼ5-fold) decrease in AKR1C1 expression was found in 13 of 24 cases. AKR1C2 expression was absent in tumors or reduced in 6 of these 13 cases. AKR1C3 expression was only significantly reduced in one case without a significant decrease in AKR1C1. SRD5A1 expression was significantly decreased in only four cases and increased (Ͼ5-fold) in three cases, and no apparent relationship existed between reduced expression of SRD5A1 and that of AKR1C1. No consistent pattern was found in the expression profile for AKR1Cs or SRD5A1 and PR, ER, Her2/neu, or Ki-67 status. Thus, reduced gene expression of ARK1C1 appears to be unrelated to PR or ER status.
Development of AKR1C-Specific Antisera and Immunohistochemical Staining in Breast Tissue Samples. Rabbits received injection with synthesized peptides to develop antisera that recognize specific family members, despite the high sequence homology of family members. Lysates harvested from permanently transfected PC-3 cells expressing AKR1C1, AKR1C3, or AKR1C2 (24) were used to assess specificity of rabbit antisera by Western blot. As illustrated in Fig. 1A , ␣1850 recognized all transfected AKR1C family members expressed in PC-3 cells. We confirmed that ␣7548, designed according to Pelleiter et al. (25) , selectively recognized only ARK1C3, whereas ␣6621 recognized both AKR1C1 and AKR1C3, but not AKR1C2. As shown in Fig. 1B , both ␣6621 and ␣7548, but not their preimmune sera, stained normal myoepithelial and luminal epithelial cells in the alveoli, which was blocked by preincubation with excess peptide, thereby confirming the specificity of IHC staining.
As illustrated in Fig. 1B , IHC staining with both ␣6621 and ␣7548 revealed predominant staining on the myoepithelial and luminal epithelial cells. Because ␣6621 cross-reacts with both AKR1C1 and ARK1C3, selective localization for AKR1C1 was determined in paired BT6 and BN6 tissue samples that lacked AKR1C3 expression. In Fig. 1C , no IHC staining with ␣7548 was observed, confirming the lack of expression of AKR1C3. IHC staining with ␣6621, which could only correspond to AKR1C1, was localized on the myoepithelial and luminal epithelial cells. Endothelial cells were also stained with this antiserum (data not shown). Decreased IHC staining was observed on the corresponding tumor sample, in close agreement with the 48-fold decrease in relative expression of AKR1C1. Thus, AKR1C1 is normally expressed in the same location as AKR1C3, with staining observed on a majority of myoepithelial and luminal epithelial cells, the latter being the same site of PR expression (3, 29) .
IHC staining with ␣6621 and ␣7548 was then performed on all available samples to determine the relationship between relative gene expression profile and protein levels. Fig. 1D illustrates two examples of paired tissue samples in which AKR1C1 mRNA expression was reduced or absent in tumor samples associated with minimal changes in AKR1C3. Decreased staining of ␣6621 in both cases corresponds with AKR1C1 expression levels, whereas ␣7548 staining for AKR1C3 was unchanged in accordance with the real-time PCR data. These cases suggest that decreased ␣6621 staining closely parallels AKR1C1 mRNA expression patterns and confirm the selectivity of ␣7548 IHC staining for AKR1C3. Fig. 1E demonstrates additional cases in which ␣6621 IHC staining matches AKR1C1 expression but not ARK1C3 expression. Finally, Fig.  1F confirms that ␣7548 staining corresponds with relative changes in AKR1C3 expression. Pathologists, who were unaware of relative expression patterns, then independently compared the IHC staining intensity of ␣6621 and ␣7548 for all available cases. Table 2 demonstrates that approximately two thirds of the ␣7548 and ␣6621 IHC staining corresponded with relative expression of AKR1C1 and AKR1C3. Taken together, these findings confirm that decreased expression of AKR1C1 mRNA identified in the tumor samples closely corresponds with loss of protein expression. Due to the lack of AKR1C2-specific antisera, we suspect (but cannot confirm) that decreased AKR1C2 mRNA will be associated with loss of protein expression.
Reduced Relative Expression of AKR1C1 in Human Breast
Cancer Cell Lines. Gene and protein levels of AKR1Cs were determined in the established human breast cancer cell lines MCF-7 and T-47D as well as in human breast epithelial cell line MCF-10A (30). As shown in Fig. 2A , significantly less AKR1C1 was found in MCF-7 and T-47D cell lines as compared with MCF-10A, whereas AKR1C3 was equivalently expressed in all cell lines. ␣7548 Western blot data in Fig. 2B confirmed that AKR1C3 was equally expressed in all cell lines, whereas use of ␣6621 showed significantly less AKR1C1 expression in MCF-7 and T-47D cell lines as compared with MCF-10A, which paralleled the AKR1C1 gene expression profile.
Progesterone Metabolism Catalyzed by AKR1C1 and AKR1C2.
To assess the role of AKR1C1 and AKR1C2 on progesterone metabolism, siRNAs were developed. Pilot results showed that Seq-A selectively suppressed AKR1C1, whereas Seq-D suppressed both AKR1C1 and AKR1C2 without affecting expression of AKR1C3, as illustrated in Fig. 2C . The ability of these two siRNAs to alter progesterone metabolism was then monitored in MCF-10A cells, Fig. 2 . Suppression of AKR1C1 and AKR1C1/AKR1C2 in T-47D cells enhanced progesterone-mediated inhibition of cellular growth. A and B, reduced expression of AKR1C1 in established breast cancer cell lines. Expression levels of AKR1C1 and AKR1C3 in the breast cancer cell lines MCF-7 and T-47D and breast epithelial cell line MCF-10A were determined at both the mRNA and protein levels by real-time PCR and Western blot. A. Relative expression of AKR1C1 and AKR1C3 was determined using real-time PCR in triplicate compared with relative levels of MCF-7 cells (arbitrarily defined as 1 Ϯ SD). Relative expression is compared with a normal breast tissue. Substantially lower AKR1C1 levels were found in MCF-7 and T-47D breast cancer cell lines as compared with breast epithelial cell line MCF-10A and a normal breast tissue. No substantial changes in AKR1C3 expression were noted in all three cell lines. B. Protein levels in breast cell lines were determined by Western blot with ␣7548 and ␣6621. Relative equivalent amounts of AKR1C3 were found in all three cell lines, whereas decreased expression of AKR1C1 was found in MCF-7 and T-47D compared with MCF-10A. CϪE. Suppression of AKR1C1 alone or with AKR1C2 reduces formation of 20␣-dihydroprogesterone from progesterone in MCF-10A. C. AKR1C1-specific siRNA (Seq-A) substantially suppressed AKR1C1 expression but not AKR1C2 and AKR1C3 in MCF-10A cells compared with nonspecific siRNA (Ns)-treated MCF-10A cells as a control. The other siRNA (Seq-D) was able to significantly suppress both AKR1C1 and AKR1C2 as compared with nonspecific siRNA-treated MCF-10A cells. AKR1C3 expression was relatively unaltered by either siRNA. D. Production of 20␣-dihydroprogesterone from progesterone in MCF-10A cells treated with AKR1C1-specific siRNA (Seq-A) or AKR1C1/AKR1C2-specific siRNA (Seq-D) was able to substantially reduce 20␣-dihydroprogesterone in both media and cell lysates. Note that the majority of the metabolite was distributed in the media. E. Decrease in 20␣-dihydroprogesterone is associated with increased progesterone in siRNA-treated cells. Suppression of both AKR1C1 and AKR1C2 leads to more unmetabolized progesterone in both cell lysates and media. which express levels of AKR1C1 comparable with those found in normal tissue. In Fig. 2D and E, suppression of AKR1C1 in MCF-10A cells significantly reduced the conversion of progesterone to 20␣-dihydroprogesterone in media and cell lysates.
Suppression of AKR1C1 and AKR1C2 leads to additional and significant inhibition of 20␣-dihydroprogesterone formation. This reduction in 20␣-dihydroprogesterone correlated with a significant increase in progesterone in both media and cell lysates.
Suppression of AKR1C1 Alone or with ARK1C2 Affects Progesterone-Mediated Inhibition of Cellular Growth of T-47D. To assess potential loss of AKR1C1 and AKR1C2 on progesterone-dependent growth, siRNA suppression of AKR1C1 and AKR1C1/AKR1C2 in T-47D cells was determined because they endogenously express PRs. In Fig. 2F , suppression of AKR1C1 alone or with AKR1C2 is illustrated. The same cells were then used for proliferation assays with progesterone treatments. As shown in Fig. 2G , no significant changes were found in those cell lines treated with siRNAs in the absence of progesterone In Fig. 2H and I, progressive inhibition of cellular proliferation was observed with suppression of both AKR1C1 and AKR1C1/AKR1C2 in the presence of 10 Ϫ9 or 10 Ϫ10 mol/L progesterone, suggesting that reduced metabolism of progesterone in T-47D is responsible for progesterone-mediated inhibition of cellular growth.
Inhibition of Progesterone-Dependent Transactivation by AKR1C1 and AKR1C2. To determine whether progesterone catabolism can alter PR-B ligand-dependent activity, the activity of a MMTV luciferase reporter gene was evaluated in the prostate cancer cell line PC-3 stably expressing AKR1C1, AKR1C2, or AKR1C3. These cells, along with PC-3 cells stably transfected with vector alone, were transiently transfected with pCMV-hPR-B, a luciferase reporter driven by the MMTV promoter, as well as a Renilla luciferase to control for transfection efficiency. In the absence of progesterone or PR-B, no activity was detectable (data not shown). In Fig. 3A , two different expression levels of AKR1C1 and AKR1C2, but not AKR1C3, in PC-3 cells were able to inhibit progesterone-dependent activation of the MMTV promoter, indicating that AKR1C1 and AKR1C2 metabolize progesterone to weaker activators of PR-B (17) . Despite low levels of AKR1C1 expression, AKR1C1 completely inhibited luciferase activity, confirming that 20␣-HSD can effectively block PR-B activation. Despite adequate levels of AKR1C3, AKR1C3 failed to inhibit progesterone-dependent activation, confirming that progesterone is a poor substrate for AKR1C3. These findings were extended to T-47D, which endogenously expresses PRs. As shown in Fig. 3B , different amounts of AKR1C1 plasmid transfected into T-47D cells together with MMTV luciferase reporter plasmid significantly inhibited luciferase activity.
DISCUSSION
Catabolism of steroid hormones can modulate availability of critical ligands for their cognate transcription factors and thereby function as effective prereceptor regulators of gene expression. This type of regulation is best characterized for the mineralocorticoid receptor, in which selective expression of 11␤-hydroxysteroid dehydrogenase type II in aldosterone target tissue prevents inappropriate activation of the mineralocorticoid receptor by cortisol (31) . A similar paradigm is also developing for the prereceptor regulation of progesterone activity by AKR1C1 (17, 31) . For example, as the human placenta comes to term, increased 20␣-HSD (but not 3␣-HSD or 17␤-hydroxysteroid dehydrogenase) activity is observed, implicating it as the major catabolic pathway for progesterone elimination (15, 16) . Besides the placenta, studies in the human kidney further support this concept because expression of AKR1C1 protects the mineralocorticoid receptor from binding with progesterone, an effective aldosterone antagonist (32, 33) . This may be especially important during pregnancy, when serum progesterone levels may reach up to 300 to 700 nmol/L by the end of the third trimester (34) . The function of AKR1C1 in the kidney may thus imitate that of 11␤-hydroxysteroid dehydrogenase type II to prevent inappropriate occupation of ligand-dependent transcription factor.
We initially assessed the relative expression of ARK1C1 and two highly related family members using a gene-specific real-time PCR. Although mRNA levels of the AKR1C family members had been quantified by semiquantitative reverse transcription-PCR and RNase protection methods (35, 36) , real-time PCR provides a reliable and highly reproducible method to monitor large changes in relative gene expression. On average, we noticed that approximately half of the 24 cases demonstrated a substantial loss of AKR1C1 expression, defined as a Ͼ5-fold reduction in tumor as compared with paired unaffected tissue. A similar reduction in AKR1C2 expression was also found in half of these cases, whereas AKR1C3 expression was relatively unchanged. Reduction in AKR1C1 expression was observed in a previous microarray study of human breast cancer, and loss of 20␣-HSD activity occurs in 7,12-dimethylbenz(a)anthracene-induced breast tumors in rats (37, 38) . Others reported a similar reduction in AKR1C1 and AKR1C2 gene expression by reverse transcription-PCR in nine breast cancer tumors as compared with unaffected surrounding tissue from the same individuals (39) . They also noted a significant increase in SRD5A1 expression in tumors as compared with normal breast tissues in contrast to our findings, which may be due to differences in the tissue sample pool sizes, stage of tumor samples, and accuracy of the RNA quantitative techniques. We confirmed that decreased protein expression of AKR1C1 was associated with the previously reported reduction in AKR1C1 gene expression in the MCF-7 and T-47D breast cancer cell lines in contrast to the breast epithelial cell line MCF-10A (35) . This pattern differed from that of AKR1C3, which was equally expressed in all cell lines. Furthermore, reduced AKR1C1 and AKR1C2 expression in MCF-10A cells by siRNA suppression leads to decreased production of 20␣-hydroxyl or 3␣-hydroxyl progesterone metabolites. Thus, decreased expression of AKR1C1 and AKR1C2 observed in human samples is mimicked in certain breast cancer cell lines, which will prove useful for future studies on the AKR1C gene family.
Cellular localization of specific AKR1C members is difficult to determine due to their high sequence similarity. Immunohistochemistry with AKR1C3-specific antiserum ␣7548 prominently stained myoepithelial and luminal epithelial cells as observed previously (25) , and AKR1C1 was localized to the same epithelial layers in samples that lacked ARK1C3 expression (25) . Although ␣6621 was able to recognize both AKR1C1 and AKR1C3 using the Western blot technique, ␣6621 IHC staining closely matched AKR1C1 gene expression, and ␣6621 IHC staining could be used to evaluate relative AKR1C1 expression in pathological samples.
The MCF-10A cell line was used to assess the physiologic function of AKR1C1 because it expresses AKR1C1 at levels comparable with those found in normal breast tissues. Selective reduction of AKR1C1 by siRNA suppression in MCF-10A leads to a decrease in conversion of progesterone to 20␣-dihydroprogesterone, present in both cell lysate and media, which was further reduced with loss of AKR1C2. Substantial decrease in 20␣-dihydroprogesterone production was associated with a corresponding increase in progesterone levels in MCF-10A cells. Progesterone-mediated inhibition of growth in T-47D cells was also observed with suppression of AKR1C1, which was further enhanced in the absence of AKR1C2 expression. The loss of these catabolic enzymes in breast cancer presumably leads to increased progesterone levels, which, in combination with increased PR, could enhance progesterone-responsive gene expression.
Confounding findings have been reported in the literature on the proliferative effects of progesterone in established human breast cell lines, with a majority of studies reporting growth-inhibitory effects (6, 28, 40 -43) . However, progesterone was found to cause cells to enter one mitotic cycle with induction of genes associated with cell growth (44, 45) . Although progestins are proliferative when administered in a transient or sequential manner, sustained treatment results in growth arrest (46) . Our data demonstrated that suppression of AKR1C1 or AKR1C1 and AKR1C2 can significantly inhibit cellular proliferation by progesterone as compared with control cell lines.
The role of progesterone as an antiproliferative agent in cell lines does not mimic its function in vivo. A majority of studies in animals and humans find that progestin treatment promotes growth in vivo (40, 47, 48) . In the recent Women Health Initiative Study, increased incidence of total and invasive breast cancer was observed in the estrogen ϩ progestin group as compared with the placebo group (7). The risks of invasive lobular carcinoma and invasive ductal carcinoma were also significantly increased among women who used combined estrogen ϩ progestin therapy (with continuous or sequential progestin use), but not among those who solely used estrogen therapy (49) , strongly implicating progesterone in combination with estrogen as stimulating cellular proliferation.
To explain how loss of AKR1C1 and AKR1C2 expression could modify progesterone-dependent PR-B activation, a progesterone-dependent MMTV reporter activity was monitored in two different cell lines. Prostate cancer PC-3 cells stably expressing either AKR1C1 or AKR1C2, but not AKR1C3, were able to reduce progesterone-dependent transactivation of the MMTV reporter construct with cotransfected PR-B. AKR1C1 was able to completely inhibit progesterone-dependent activity, despite its low level of expression. Increasing concentrations of progesterone were able to overcome this kind of inhibition (data not shown), indicating that metabolism, not some nonspecific process, is responsible for reduced PR-B activation. Studies in the T-47D cell line confirmed that AKR1C1 was able to inhibit progesterone-dependent PR-B activation in a breast-derived cell line. In addition to 20␣-HSD, the 3␣-HSD of AKR1C2 can also inhibit progesterone-dependent activation of PR-B, although not as effectively as AKR1C1.
In normal breast tissues, AKR1C1 is localized predominately in the myoepithelial cells and in the luminal epithelial cells, which also express PR (3, 50) . We speculate that expression of AKR1C1 and possibly AKR1C2 in normal tissue may regulate progesterone-dependent gene expression by limiting progesterone's interactions with nuclear PRs. This observation resembles our recent finding of selective reduction in AKR1C2 expression, but not ARK1C3, in prostate cancer samples (24) , suggesting that specific yet highly related AKR1C family members can act as prereceptor regulators for ligand-dependent transcription factors. Thus, AKR1C1 may limit progesterone-dependent signaling of nuclear PRs and thereby indirectly regulate gene expression. This is compatible with the role of AKR1C1 to limit the inhibitory interactions of progesterone with mineralocorticoid receptor.
We hypothesize that loss of key catabolic enzymes in breast cancer tissues in combination with increased expression of PR may enhance progesterone-dependent gene expression. In addition to increased progesterone levels and differences in progesterone metabolites as a result of loss of AKR1C1 or AKR1C2, changes in relative expression of PR-A and PR-B in breast cancer could also alter the spectrum of progesteroneregulated genes (51). Wiebe et al. (28, 35) have also reported a differential effect of specific progesterone metabolites as either growth promoters or inhibitors of the cell cycle in the MCF-7 cell line, suggesting a specific role for progesterone metabolites. The appearance of specific progesterone metabolite binding sites on MCF-7 membranes further supports a role for progesterone metabolites as signaling molecules (52) . Thus, metabolites of progesterone may also have unsuspected effects on cell growth. Fig. 4 illustrates the potential role of AKR1C1 and AKR1C2 functioning as a prereceptor regulator of progesterone interactions with PRs. Loss of AKR1C1 in combination with increased PR in selective breast cancers could therefore provide therapeutic opportunities to block ligand-dependent activation of PRs by using antiprogestational agents.
